Transparent interactions
Working with healthcare professionals and patients
We are committed to transparency. Therefore, we disclose the transfers of value we make to individual healthcare professionals and patients and to their respective organizations. We work with healthcare professionals and patient organizations to deliver new treatment options within brain diseases and our interactions are well-regulated.
Strength in collaboration
To develop and deliver innovative treatment of brain disease, we work with a range of stakeholders. These include healthcare professionals, patients and their respective organizations. We collaborate on research, clinical development, exchange of scientific information, and marketing and sales activities.
These interactions are well-regulated by the national laws and industry association regulations that we integrate into our working processes, training and guidance.
We are committed to transparency and our disclosed information follows the current laws or regulations from the industry associations we have joined, such as the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Dialogue with decision makers in Denmark
According to the Ethical rules for dialogue and negotiations with decision-makers published by Danish Ethical Committee for the Pharmaceutical Industry, every pharmaceutical company is obliged to publish a schedule on their website with the names of the PR or communication agencies, legal counsel or similar external consultancies acting on behalf of the pharmaceutical company to engage in dialogue and negotiations with decision-makers.
The following external consultants are representing H. Lundbeck A/S in dialogue and negotiation with decision makers:
Rud Pedersen Public Affairs
Christians Brygge 24, 3.
DK- 1559 København V
Lead Agency
Ravnsborg Tværggade 5c, 1.
DK-2200 København N
We have made the external agencies aware of the present set of rules and that the pharmaceutical company accepts responsibility for ensuring third party compliance therewith.
Transfers of value to healthcare professionals and patient organizations
Here you can find an overview, together with the locations, of Lundbeck’s interactions with healthcare professionals and the related transfers of value:
Countries that disclose
Aggregate disclosures
Lundbeck discloses payments and other transfers for value to HCPs and HCOs in aggregate, if the HCP or HCO has used their legal right to refuse consent to individual disclosure, in accordance with the EFPIA Disclosure Code. The data covers Lundbeck affiliates that use Lundbeck’s corporate website for disclosure. Data from other countries can be found on the Country overview tab.
Historic research and development disclosures
Lundbeck undertakes research activities and conducts clinical studies globally. Clinical studies are conducted in accordance with international guidelines and performed by HCPs and HCOs. Our payments and other transfers of value related to pre-clinical, clinical and non-interventional studies are disclosed in aggregate.
| Country | 2020 | 2021 |
| Bulgaria | €745,539 | €403,565 |
| Croatia | €5,101 | - |
| Estonia | - | - |
| Hungary | €52,343 | €46,635 |
| Latvia | - | - |
| Lithuania | - | - |
| Ukraine | €413,939 | €232,245 |
The amounts cover payments and other transfers of value to HCPs and HCOs related to pre-clinical, clinical and non-interventional studies in the countries where the Lundbeck affiliate uses Lundbeck’s corporate website for disclosure in accordance with the EFPIA Disclosure Code.
Data from other countries can be found under countries that disclose.
H. Lundbeck A/S collaboration with Patient Organizations (Samarbejde med Patientforeninger)
| Samarbejds-projektets navn | Navnet på de parter, der har indgået aftalen | Type af projekt | Formål | Parternes rolle i projektet | Tidsramme | Den økonomiske støttes størrelse | Omfang og indhold af betydelig ikke-finansiel støtte | |||||||
| Donation to Livslinien for Communication project 2023-2025 | Livslinien | Donation | Livslinien wants to ensure that more people in need of help know about the counseling at Livslinien, and continuously makes effort to inform about the possibility. Donation will be used for communication project. (1. design, layout and graphic materials, 2. including image and video material, and 3. advertising) | Donation from H. Lundbeck A/S | 01.12.2022 - 30.01.2026 | DKK 100.000 | N/A | |||||||
| Donation to Hjerneskadeforeningen | Hjerneskadeforeningen | Sponsorship | The project aims to gauge interest among politicians, professionals, patient organizations, municipalities, and regions in working towards a national brain plan | Sponsorship form H. Lundbeck A/S | 2025 | DKK 100.000 | N/A | |||||||
| ”Don’t fear the Weird” filmfestival | Foreningen Outsideren | Sponsorship | The purpose of the “Don´t Fear the Weird” Filmfestival’ is to create public awareness of people living with brain health conditions and to create hope for others who are experiencing mental difficulties. The support provided by Lundbeck is used on organizing awareness workshops and production of videos for the Filmfestival. | Sponsorship from H. Lundbeck A/S | 2025 | DKK 25.000 | N/A |
H. Lundbeck A/S donnations to Hospitals (Donationer til Hospitaler)
| Overskrift på donation | Navn(e) på hospital og/eller afdeling(er) | Hvad donation ydes til | Formål | Tidshorisont | Beløb | Naturalier | ||||||
| ACTH levels in healthy children | Rigshospitalet | Funding for research project | Investigating ACTH levels in healthy children | 08/02/2024 – 30/06/2025 | DKK 369.345 | N/A | ||||||
| “Fueling up brain energy supply in Multiple System Atrophy for slowing down α-syn pathology” | Bispebjerg Hospital | Contribution to PhD study | The purpose of the project is 1. To establish improved cellular and animal models of MSA displaying key features of MSA, especially GCI-like α-syn aggregations. 2. To investigate the effects of modulating glucose metabolism and inflammation in α-syn pathology progression, using the models generated. | 2022-2025 | DKK 68.639 | N/A |
More from Lundbeck
Responsible business conduct
We pursue our business purpose guided by several pillars and our Code of Conduct.
Clinical data sharing
Our policy for scientific publications and responsible clinical data sharing.
Patients
We see patients as people and are committed to support the person behind.